Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

medicines access

- PMLiVE

Johnson & Johnson agrees $700m settlement to resolve talcum powder investigations

The deal would resolve US states’ probes into the marketing of its talcum products

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

Johnson & Johnson’s bladder cancer drug Balversa granted full FDA approval

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Novartis shares positive phase 3 results for Lutathera in neuroendocrine tumours

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

Merck expands cancer immunotherapy pipeline with $680m Harpoon acquisition

The deal includes a T-cell engager for lung cancer and neuroendocrine tumours

- PMLiVE

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn

The deal includes an ADC candidate in clinical development to treat advanced prostate cancer

- PMLiVE

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

Beyfortus showed an over 80% reduction in hospitalisations associated with the virus

- PMLiVE

Novartis shares positive phase 3 results for Scemblix in chronic myeloid leukaemia

More than 6,300 people are diagnosed with the disease every year in Europe

- PMLiVE

Merck gains rights to Inspirna’s colorectal cancer drug for $45m upfront

Ompenaclid is in phase 2 development to treat advanced or metastatic colorectal cancer

- PMLiVE

AstraZeneca and Ionis’ Wainua granted FDA approval for rare disease ATTRv-PN

ATTRv-PN leads to peripheral nerve damage with motor disability within five years of diagnosis

- PMLiVE

Novartis and Voyager enter gene therapy partnership worth over $1.2bn

The companies will advance candidates for Huntington’s disease and spinal muscular atrophy

- PMLiVE

AstraZeneca to acquire cell therapy specialist Gracell in deal worth up to $1.2bn

The transaction includes a clinical-stage candidate being evaluated as a treatment for multiple myeloma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links